The USFDA has approved imlunestrant for the treatment of adult patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy (ET). Imlunestrant is an oral estrogen receptor antagonist that inhibits ER-dependent gene transcription and cellular proliferation. Clinical evidence In a clinical trial of 256 patients (median age: 61 years), imlunestrant significantly reduced the risk of disease progression or death by 38% compared with ET.
Median progression-free survival was 5.5 months with imlunestrant versus 3.8 months with ET. Dosage and administration Available as 200mg tablets Recommended dose: 400 mg orally once daily on an empty stomach Reduce the dose in patients with moderate or severe…
